The Efficacy of Semaglutide on Hypothalamic Obesity Caused by Craniopharyngioma Surgery
Authors' conclusion
Semaglutide demonstrated significant effects on weight loss in patients with hypothalamic obesity with craniopharyngioma surgery, providing a viable option for managing obesity in this population.
Study context
- Population
- Patients with obesity after craniopharyngioma surgery attending outpatient endocrinology, Peking Union Medical College Hospital, March 2023 to October 2024
- Participants
- 23 patients
- Exposure
- Semaglutide vs lifestyle intervention alone
- Semaglutiden = 14
- Controln = 9reference
- Outcome
- Weight reduction
- Follow-up
- 3 and 6 months
Methodological detailssingle-centre, non-randomised
- Single-centre
- Non-randomised
Main finding
As reported in the abstract
Weight · baseline vs 3 and 6 months
Semaglutide: weight at baseline vs 3 months (p < 0.001)
108.9 ± 20.9 kg vs. 100.8 ± 20.2 kg
Semaglutide: weight at baseline vs 6 months (p < 0.001)
108.9 ± 20.9 kg vs. 96.1 ± 23.1 kg
Observational data: associations, not effects.
Further findings
Weight loss >5%, Semaglutide
- After 3 months
- 64.3%
- After 6 months
- 90%
Original publication
The Efficacy of Semaglutide on Hypothalamic Obesity Caused by Craniopharyngioma Surgery. Clin Endocrinol (Oxf). Published 27 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →